M6A regulators are associated with tumor resistance, and patients exhibit higher tolerance to tyrosine kinase inhibitor (TKI) during TKI therapy because of reduced m6A due to FTO overexpression in leukemia cells (174). The gene discussed is METTL3; the disease is leukemia.